Journal article · 2022
Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases
Journal of Medicinal Chemistry, 65(13), 8828–8842 · Published 29 June 2022 · DOI 10.1021/acs.jmedchem.2c00422
In brief
“Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases” is a 2022 journal article by Mark D. Andrews and 6 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 38 citations as of 21 November 2026, which puts it in the top 7% of works published in 2022 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 38
- Most cited in
- 2025 (12)
- Field-weighted impact
- 2.44
- References
- 45
- Authors
- 7
Abstract
Interleukin 17A (IL-17A) is an interleukin cytokine whose dysregulation is implicated in autoimmune disorders such as psoriasis, and monoclonal antibodies against the IL-17A pathway are now well-established and very effective treatments. This article outlines the work that led to the identification of 23 as an oral, small-molecule protein–protein interaction modulator (PPIm) clinical development candidate. Protein… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022). Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases. Journal of Medicinal Chemistry, 65(13), 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422
MLA 9
Andrews, Mark D., et al. “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases.” Journal of Medicinal Chemistry, vol. 65, no. 13, 2022, pp. 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422.
Chicago
Andrews, Mark D., Kevin Neil Dack, Marcel John de Groot, Maja Lambert, Carl Johan Sennbro, Mogens Larsen, and Martin Stahlhut. 2022. “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases.” Journal of Medicinal Chemistry 65 (13): 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422.
Harvard
Andrews, M. D. et al. (2022) ‘Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases’, Journal of Medicinal Chemistry, 65(13), pp. 8828–8842. doi:10.1021/acs.jmedchem.2c00422.
IEEE
M. D. Andrews et al., “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases,” Journal of Medicinal Chemistry, vol. 65, no. 13, pp. 8828–8842, 2022, doi: 10.1021/acs.jmedchem.2c00422.
BibTeX
@article{andrews2022discovery,
title = {{Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases}},
author = {Andrews, Mark D. and Dack, Kevin Neil and de Groot, Marcel John and Lambert, Maja and Sennbro, Carl Johan and Larsen, Mogens and Stahlhut, Martin},
journal = {Journal of Medicinal Chemistry},
year = {2022},
volume = {65},
number = {13},
pages = {8828--8842},
doi = {10.1021/acs.jmedchem.2c00422},
url = {https://doi.org/10.1021/acs.jmedchem.2c00422}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 2 | |
| 2023 | 4 | |
| 2024 | 11 | |
| 2025 | 12 | |
| 2026 | 9 |
Its field-weighted citation impact is 2.44: it has been cited 2.44 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- IL-17A
- psoriasis
- oral bioavailability
- Rule of 5
- small molecule drug discovery
- structure-activity optimization
- inflammatory diseases
- monoclonal antibody alternatives
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022). Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases. Journal of Medicinal Chemistry, 65(13), 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422
How many times has this paper been cited?
38 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Mark D. Andrews, Kevin Neil Dack, Marcel John de Groot, Maja Lambert, Carl Johan Sennbro, Mogens Larsen, Martin Stahlhut.
What is the DOI of this paper?
10.1021/acs.jmedchem.2c00422, permanently at https://doi.org/10.1021/acs.jmedchem.2c00422. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.